Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy

Nicolas J. Llosa, Brandon Luber, Nicholas Siegel, Anas H. Awan, Teniola Oke, Qingfeng Zhu, Bjarne R. Bartlett, Laveet K. Aulakh, Elizabeth D. Thompson, Elizabeth M. Jaffee, Jennifer N. Durham, Cynthia L. Sears, Dung T. Le, Luis A. Diaz, Drew M. Pardoll, Hao Wang, Franck Housseau, Robert A. Anders

Research output: Contribution to journalArticle

Abstract

Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability–high (MSI-H) cancer. Despite this success, a large majority of metastatic colorectal cancer patients are not MSI-H and do not benefit from checkpoint blockade treatment. Predictive biomarkers to develop personalized medicines and guide clinical trials are needed for these patients. We, therefore, asked whether immunohistologic stratification of metastatic colorectal cancer based on primary tumor PD-L1 expression associated with the presence or absence of extracellular mucin defines a subset of metastatic colorectal cancer patients who exhibit a preexisting antitumor immune response and who could potentially benefit from the checkpoint blockade. To address this, we studied 26 advanced metastatic colorectal cancer patients treated with pembrolizumab (NCT01876511). To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. When validated in larger cohorts, the CPM score in combination with MSI testing may guide immunotherapy interventions for colorectal cancer patient treatment.

Original languageEnglish (US)
Pages (from-to)1574-1579
Number of pages6
JournalCancer Immunology Research
Volume7
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Immunotherapy
Colorectal Neoplasms
Mucins
Microsatellite Repeats
Neoplasms
Precision Medicine
Standard of Care
Biomarkers
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy. / Llosa, Nicolas J.; Luber, Brandon; Siegel, Nicholas; Awan, Anas H.; Oke, Teniola; Zhu, Qingfeng; Bartlett, Bjarne R.; Aulakh, Laveet K.; Thompson, Elizabeth D.; Jaffee, Elizabeth M.; Durham, Jennifer N.; Sears, Cynthia L.; Le, Dung T.; Diaz, Luis A.; Pardoll, Drew M.; Wang, Hao; Housseau, Franck; Anders, Robert A.

In: Cancer Immunology Research, Vol. 7, No. 10, 01.01.2019, p. 1574-1579.

Research output: Contribution to journalArticle

@article{6bc649fae1244451a87984ea7cc6eccc,
title = "Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy",
abstract = "Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability–high (MSI-H) cancer. Despite this success, a large majority of metastatic colorectal cancer patients are not MSI-H and do not benefit from checkpoint blockade treatment. Predictive biomarkers to develop personalized medicines and guide clinical trials are needed for these patients. We, therefore, asked whether immunohistologic stratification of metastatic colorectal cancer based on primary tumor PD-L1 expression associated with the presence or absence of extracellular mucin defines a subset of metastatic colorectal cancer patients who exhibit a preexisting antitumor immune response and who could potentially benefit from the checkpoint blockade. To address this, we studied 26 advanced metastatic colorectal cancer patients treated with pembrolizumab (NCT01876511). To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. When validated in larger cohorts, the CPM score in combination with MSI testing may guide immunotherapy interventions for colorectal cancer patient treatment.",
author = "Llosa, {Nicolas J.} and Brandon Luber and Nicholas Siegel and Awan, {Anas H.} and Teniola Oke and Qingfeng Zhu and Bartlett, {Bjarne R.} and Aulakh, {Laveet K.} and Thompson, {Elizabeth D.} and Jaffee, {Elizabeth M.} and Durham, {Jennifer N.} and Sears, {Cynthia L.} and Le, {Dung T.} and Diaz, {Luis A.} and Pardoll, {Drew M.} and Hao Wang and Franck Housseau and Anders, {Robert A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/2326-6066.CIR-18-0927",
language = "English (US)",
volume = "7",
pages = "1574--1579",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy

AU - Llosa, Nicolas J.

AU - Luber, Brandon

AU - Siegel, Nicholas

AU - Awan, Anas H.

AU - Oke, Teniola

AU - Zhu, Qingfeng

AU - Bartlett, Bjarne R.

AU - Aulakh, Laveet K.

AU - Thompson, Elizabeth D.

AU - Jaffee, Elizabeth M.

AU - Durham, Jennifer N.

AU - Sears, Cynthia L.

AU - Le, Dung T.

AU - Diaz, Luis A.

AU - Pardoll, Drew M.

AU - Wang, Hao

AU - Housseau, Franck

AU - Anders, Robert A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability–high (MSI-H) cancer. Despite this success, a large majority of metastatic colorectal cancer patients are not MSI-H and do not benefit from checkpoint blockade treatment. Predictive biomarkers to develop personalized medicines and guide clinical trials are needed for these patients. We, therefore, asked whether immunohistologic stratification of metastatic colorectal cancer based on primary tumor PD-L1 expression associated with the presence or absence of extracellular mucin defines a subset of metastatic colorectal cancer patients who exhibit a preexisting antitumor immune response and who could potentially benefit from the checkpoint blockade. To address this, we studied 26 advanced metastatic colorectal cancer patients treated with pembrolizumab (NCT01876511). To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. When validated in larger cohorts, the CPM score in combination with MSI testing may guide immunotherapy interventions for colorectal cancer patient treatment.

AB - Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability–high (MSI-H) cancer. Despite this success, a large majority of metastatic colorectal cancer patients are not MSI-H and do not benefit from checkpoint blockade treatment. Predictive biomarkers to develop personalized medicines and guide clinical trials are needed for these patients. We, therefore, asked whether immunohistologic stratification of metastatic colorectal cancer based on primary tumor PD-L1 expression associated with the presence or absence of extracellular mucin defines a subset of metastatic colorectal cancer patients who exhibit a preexisting antitumor immune response and who could potentially benefit from the checkpoint blockade. To address this, we studied 26 advanced metastatic colorectal cancer patients treated with pembrolizumab (NCT01876511). To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. When validated in larger cohorts, the CPM score in combination with MSI testing may guide immunotherapy interventions for colorectal cancer patient treatment.

UR - http://www.scopus.com/inward/record.url?scp=85072848790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072848790&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-18-0927

DO - 10.1158/2326-6066.CIR-18-0927

M3 - Article

C2 - 31439614

AN - SCOPUS:85072848790

VL - 7

SP - 1574

EP - 1579

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 10

ER -